Regarding TNM stages, CYP2W1 expression was observed in 48.0% (12/25) of Stage III STS tumors and 71.4% (5/7) of Stage IV STS tumors, whereas no expression was detected in Stage II or Stage I tumors (0/5 each). This evidence concerns the gene CYP2W1 and telomere syndrome.